Hydroxychloroquine
Brand names: Plaquenil
Hydroxychloroquine, an antimalarial and disease-modifying agent, used in the obstetric setting chiefly for maternal autoimmune disease such as systemic lupus erythematosus and antiphospholipid syndrome, where it is generally continued through pregnancy.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Hydroxychloroquine accumulates in lysosomes and interferes with antigen processing and toll-like receptor signalling, producing immunomodulatory and anti-inflammatory effects that reduce lupus disease activity.
Prescribing in practice
- It is regarded as compatible with pregnancy and breastfeeding and stopping it abruptly can precipitate a maternal lupus flare, so continuation is usually advised after specialist discussion.
- Long-term use carries a risk of irreversible retinal toxicity, warranting baseline and periodic ophthalmic screening.
- Rare cardiac conduction effects and QT prolongation can occur, with caution where other QT-prolonging drugs are co-prescribed.
Monitoring
Arrange retinal screening per ophthalmology recommendations for long-term users and monitor maternal disease activity through the pregnancy.
Counselling the patient
- Keep taking this medicine in pregnancy unless your specialist tells you otherwise, as stopping can worsen your condition.
- Attend your eye screening appointments and report any change in vision.
- It is taken regularly to control your condition rather than for immediate symptom relief.
Evidence & guidelines
Rheumatology and obstetric guidance supports continuing hydroxychloroquine in pregnancy for lupus, reflecting evidence that it reduces flares and adverse pregnancy outcomes.
Reference: MHRA hydroxychloroquine retinopathy guidance 2020; Izmirly et al. NEJM 2020 (PATCH trial); BSR/BHPR SLE in Pregnancy Guideline (2022); EULAR APS Guidelines (2019); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Modified Obstetric Early Warning Score (MEOWS) · Maternal Deterioration
- HELLP Syndrome Diagnostic Criteria · Hypertensive Disorders
- Pre-eclampsia Risk Screening (NICE NG133) · Obstetric Complications
- Bishop Score (Cervical Ripeness for Induction) · Labour and Delivery
- Placenta Praevia / Accreta Risk Assessment · Obstetric Complications
- MOEWS — Modified Obstetric Early Warning Score · Maternal Surveillance